Here's a real-world comparison of the weight loss data we have: Semaglutide 2.4 mg (Wegovy): ~15% body weight loss at 68 weeks in the STEP 1 trial Tirzepatide 15 mg (Zepbound): ~22.5% body weight loss at 72 weeks in SURMOUNT-1 Retatrutide 12 mg: ~24.2% body weight loss at 48 weeks in Phase 2 (shorter trial, remember) Promising, but still unproven at scale
Additionally, GIP is suggested to regulate glucose homeostasis by stimulation of pancreatic alpha cells to secrete glucagon during euglycemia and hypoglycemia (17)
It may support overall fat loss, but it doesnt specifically target belly fat
[PMID: 40610021] PubMed record related to this compound for laboratory literature review
61,329 Happy patients served
Walter RB, Hoofnagle AN, Lanum SA, Collins SJ